How Are Mutations and Biomarkers Described in Chinese Molecular Reports?
A Chinese molecular pathology report lists genetic changes found in the tumor and classifies their clinical significance. The most dangerous misreadings are not the gene names — they are the classification terms: reading “意义未明” (uncertain significance) as “problematic,” or “未检出” (not detected) as “nothing is wrong.” This page explains the structure of these reports and the terms that most often lead to misunderstanding.
Quick Answer
A Chinese molecular report typically has four key parts: sample information (样本类型, yàng běn lèi xíng — tissue, blood, or fluid), detected variants (检出变异, jiǎn chū biàn yì — the specific gene changes found), variant classification (变异分级, biàn yì fēn jí — pathogenic, likely pathogenic, uncertain significance, likely benign, or benign), and clinical interpretation (临床意义, lín chuáng yì yì — whether the variant is actionable). The most dangerous misreadings are: treating “意义未明” (VUS) as a confirmed problem, treating “未检出” (not detected) as proof that no mutation exists, and treating “致病性” (pathogenic) as meaning a treatment is definitely available. A molecular report describes what was found in the tested sample — it does not prescribe a treatment.
“A mutation means I have a target for a drug.” — Not necessarily. A pathogenic variant is a change that affects gene function, but it is only actionable if there is an approved therapy for that specific variant in that specific cancer type. Many pathogenic variants have no corresponding drug. And a “variant of uncertain significance” is not a problem to solve — it is a finding the laboratory cannot yet classify. Reading either term as a treatment answer is a misreading of the report’s purpose.
Who This Page Is NOT For
This page is not a tool to interpret your own molecular report, and it is not a substitute for the explanation given by the molecular pathologist or your treating oncologist. It is for patients and families who have received a Chinese molecular report and want to understand its structure and terminology — so they can ask better questions of their treating team. Only the molecular pathologist and your treating oncologist can interpret the report for your specific case.
The Four Parts of a Chinese Molecular Report
Most Chinese molecular reports follow a standard structure. Knowing the parts helps you find the information you need — and helps you notice what is missing.
1. 样本类型 — Sample type
What was tested: tumor tissue, blood, or body fluid. The sample type affects what the test can detect.
- 组织 (tissue) — usually the preferred sample
- 血液 (blood) — used for ctDNA or when tissue is unavailable
- 胸水/腹水 (pleural/ascitic fluid) — sometimes used
2. 检出变异 — Detected variants
The specific gene changes found, written in standard nomenclature (for example, EGFR L858R).
- Gene name and specific change
- Variant allele frequency (VAF), if reported
- Type: substitution, insertion, deletion, fusion, amplification
3. 变异分级 — Variant classification
How the laboratory classifies the clinical significance of each variant.
- 致病性 (pathogenic)
- 可能致病 (likely pathogenic)
- 意义未明 (VUS)
- 可能良性 / 良性 (likely benign / benign)
4. 临床意义 — Clinical interpretation
Whether the variant is actionable — that is, whether it may open or close specific treatment categories.
- 可靶向 (actionable / targetable)
- 与预后相关 (prognostic)
- 与免疫治疗相关 (immunotherapy-related)
- 无明确临床意义 (no clear clinical significance)
Terms Most Often Misread
| Chinese term | Pinyin | Approximate English | Why it is easy to misread |
|---|---|---|---|
| 突变 / 变异 | tū biàn / biàn yì | Mutation / variant | “Variant” is now the preferred term because “mutation” sounds like it always causes disease. A variant can be pathogenic, benign, or of uncertain significance. |
| 致病性 | zhì bìng xìng | Pathogenic | Means the variant affects gene function. It does not mean a treatment is available. Many pathogenic variants have no corresponding drug. |
| 意义未明 | yì yì wèi míng | Variant of uncertain significance (VUS) | Means the laboratory cannot yet classify the variant. It is not a “problem” and not a “normal” result. It is an open question, not a conclusion. |
| 未检出 | wèi jiǎn chū | Not detected | Means the test did not detect the target. It does not mean the variant is absent — sensitivity, sample quality, and method all matter. |
| 可靶向 / 可用药 | kě bǎ xiàng / kě yòng yào | Actionable / targetable | Means there is a potential drug match — not a guarantee of response, and not a guarantee of access in your country. |
| 突变丰度 / VAF | tū biàn fēng dù / VAF | Variant allele frequency | The percentage of DNA copies carrying the variant. It helps estimate tumor content and distinguish germline from somatic variants, but it is not a measure of “how bad” the cancer is. |
| 胚系 / 体细胞 | pēi xì / tǐ xì bāo | Germline / somatic | Germline variants are inherited and present in every cell; somatic variants are acquired and present in the tumor. The two have different implications for family members and for treatment. |
| 融合 | róng hé | Fusion | Two genes joined abnormally. Some fusions are actionable (for example, ALK, ROS1, NTRK); others are not. The specific fusion matters. |
| 扩增 | kuò zēng | Amplification | An increase in gene copy number (for example, HER2 amplification). Amplification does not always mean the gene is driving the cancer. |
| 微卫星不稳定 / MSI | wēi wèi xīng bù wěn dìng / MSI | Microsatellite instability | MSI-High (MSI-H) is associated with response to immunotherapy in some cancer types. MSI-Stable (MSS) does not rule out immunotherapy, but it is a different starting point. |
A Fictional Example: Reading a Molecular Report Entry
The example below is fictional. It is used only to show how a variant entry and its classification appear in a molecular report. It is not derived from any real patient’s records.
How to read this example: The sample type tells you what was tested. The detected variant tells you the exact gene change (EGFR L858R) and the VAF (32%). The classification “致病性（Ⅰ类）” means the laboratory considers this a pathogenic variant with clear clinical significance. The clinical interpretation says it is a sensitizing target for EGFR TKIs — but it does not tell you which drug to take, at what dose, or whether that drug is available where you live. Those are questions for your treating oncologist. The report tells you what was found; the treatment decision is made with your clinical team.
Questions to Bring to Your Doctor
These questions are educational. They are not an assessment of your case. Review the answers with your licensed oncologist and, where appropriate, the molecular pathologist who issued the report.
What was the sample type, and was it adequate for this test?
Ask whether the sample quality and tumor content were sufficient, and whether a repeat test is needed.
Which detected variants are classified as pathogenic or likely pathogenic?
Ask for the classification of each variant, and whether any are actionable in your cancer type.
If a variant is “意义未明” (VUS), what does that mean for my treatment?
Ask whether the VUS affects any treatment decision, and whether reclassification is expected over time.
If a result is “未检出” (not detected), does that rule out the variant?
Ask about the test sensitivity and whether a different sample or method might detect it.
Is the variant germline or somatic, and does it have implications for my family?
Germline variants may warrant genetic counseling for relatives. Ask whether this applies to your result.
If a variant is actionable, is the corresponding drug approved and available where I am treated?
Actionability is not the same as access. Ask about local approval, reimbursement, and clinical trial options.
Continue Your Research
Related reference pages on Chinese medical documents and cancer diagnosis.
What Do 符合, 考虑为, 倾向, and 不除外 Mean?
How four modifier terms express different levels of diagnostic certainty in a Chinese pathology report.
How Do I Match a Chinese Drug Name to Its Generic Name?
Identify a Chinese cancer drug by brand, active ingredient, or generic name.
How Do I Read a Chinese Oncology Laboratory Report?
Blood counts, tumor markers, and molecular results — each term covered from test name and units to plain-language meaning.
Frequently Asked Questions
Does a “pathogenic” variant mean I have a treatment option?
Not necessarily. “Pathogenic” means the variant affects gene function. It becomes actionable only if there is an approved therapy for that specific variant in that specific cancer type, and if that therapy is available where you are treated. Many pathogenic variants have no corresponding drug. The report’s “clinical interpretation” section should tell you whether the variant is considered actionable — but the treatment decision is made by your oncologist.
What does “意义未明” (VUS) mean, and should I worry?
“意义未明” means variant of uncertain significance. The laboratory found a change but cannot yet classify it as pathogenic or benign, usually because there is not enough data about that specific change. It is not a “problem” and not a “normal” result — it is an open question. VUS are often reclassified over time as more data accumulate. Ask your oncologist whether the VUS affects any treatment decision in your case.
Does “未检出” (not detected) mean there is no mutation?
No. “未检出” means the test did not detect the target under the conditions used. It does not prove the variant is absent. The variant may be below the detection threshold, the sample may have had low tumor content, or the test may not cover that specific variant. If the result matters for a treatment decision, ask your oncologist whether a different sample or a more sensitive test would be appropriate.
What is the difference between germline and somatic variants?
Germline variants are inherited and present in every cell of the body. Somatic variants are acquired and present only in the tumor (or in a subset of cells). The distinction matters because germline variants can have implications for family members (who may also carry the variant), while somatic variants do not. If a germline variant is identified, your treating team may recommend genetic counseling for you and your relatives.
What does VAF (突变丰度) mean?
VAF stands for variant allele frequency — the percentage of DNA copies in the sample that carry the variant. It helps estimate the proportion of tumor cells in the sample and can help distinguish germline from somatic variants (a VAF near 50% or 100% may suggest a germline variant). It is not a direct measure of how aggressive the cancer is. Interpretation of VAF depends on the sample type and the clinical context.
Where can I find the full list of Chinese medical document reference pages?
This page is part of a series of question-based reference pages on Chinese medical documents. Related pages cover pathology certainty terms, drug-name matching, high-risk mistranslation terms, discharge summaries, laboratory reports, CAR-T records, imaging reports, clinical trial documents, and prescription units. You can find the full list on the Evidence Hub.
Sources & References
- 金域医学. 血液学年会丨覆盖DNA&RNA，血液肿瘤NGS报告解读干货来了. 2025-09-17. (Includes AMP variant classification tiers: Class I–IV; VAF interpretation; FLT3-ITD, CEBPA, TP53 special rules.) kingmed.com.cn ↗
- The Jackson Laboratory. Cancer Biomarker Report Terms. May 2026. (Includes variant types, classification categories — benign, pathogenic, VUS — and MSI/MMR/PD-L1/TMB terminology.) jax.org ↗
- MyPathologyReport.ca. 了解癌症中的下一代测序 (NGS). 2026-10-12. (Includes plain-language explanations of variants, fusions, copy number changes, VAF, and “no reportable alterations.”) mypathologyreport.ca ↗
- 肿瘤二代测序临床报告解读共识. Jebm. 2022. (Includes germline variant classification levels, TMB definitions, and the distinction between somatic and germline variants.) jebm.cn ↗
- 新福建. 免疫组化、分子检测 病理报告里的“精准诊断密码”. 2026-06-10. (Includes the relationship between conventional pathology, IHC, and molecular testing, and the role of molecular testing in guiding targeted therapy.) fjwsb.fjdaily.com ↗